Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » Hamamatsu Pharma Research

Hamamatsu Pharma Research

Table of Contents
Table of Contents

Hamamatsu Pharma Research specializes in non-clinical studies using non-human primates (NHPs).

This page showcases key features of the company’s non-clinical capability, examples of disease models, and case studies.

We hope it serves as a useful reference when you are selecting a non-clinical CRO.

Non-clinical Model Available at Hamamatsu Pharma Research

High-precision pharmacological study using non-human primates (NHPs)

EPHamamatsu Pharma Research specializes in non-clinical models with non-human primates such as crab-eating macaques—the experimental animals most closely related to humans.

By overcoming the limitations of conventional small animal models such as mice, the company has improved the accuracy of efficacy predictions in humans.

These studies are especially reliable in areas where human-like models are essential, including central nervous system (CNS) disorders and rare diseases.

Drug discovery support using unique disease models and the PIT method

In collaboration with Hamamatsu University School of Medicine, the company provides high-precision non-clinical studies utilizing the university’s proprietary “PIT method” and can offer co-development of new model or established disease models.

Their research covers a wide range of disease areas, including exudative and atrophic age-related macular degeneration, osteoarthritis of the knee, anti-tumor drug-induced neuropathic pain, cerebral infarction, and Parkinson’s disease.

Even when a candidate drug shows limited efficacy, the obtained data can provide valuable insights for the future research and development.

Experienced researchers and full ethical accreditation

The company is equipped with teams of specialized researchers with advanced expertise in primate handling and testing.

They offer flexible work flow that allows for last-minute protocol modifications if necessary.

Hamamatsu Pharma Research is fully accredited by AAALAC International standard, ensuring the highest standards of animal welfare, ethics, and safety.

Contract Research Partners of Hamamatsu Pharma Research

No information regarding partnered organizations was found on the official website.

Case Studies of Non-clinical Trials

Pharmacological studies for central nervous system diseases

Hamamatsu Pharma Research focuses on the development of experimental models for focal cerebral ischemia (acute and chronic) and Parkinson’s disease in small animals and monkeys.
For cerebral infarction, they offer middle cerebral artery (MCA) thrombus, permanent occlusion, transient occlusion, and embolization models, which enable quantification of infarct size and functional assessments.
For Parkinson’s disease, available models include the systemic MPTP administration model and the MPTP hemiparkinsonism model.

Reference: Hamamatsu Pharma Research official website
https://www.hpharma.jp/service/pharmacology/central-nervous/

Pharmacological studies for cardiovascular diseases

The company has developed various thrombosis models, including the PIT model (Photochemically Induced Thrombosis).
It can produce mural thrombi through balloon injury and perform quantitative evaluation using diagnostic ultrasound and MRI imaging technologies.

Reference: Hamamatsu Pharma Research official website
https://www.hpharma.jp/service/pharmacology/circulatory/

Company Information

Hamamatsu Pharma Research focuses exclusively on non-clinical pharmacological testing and is actively engaged in research and development within this field.

Address 1-3-7 ShinMiyakoda, Hamana-ku, Hamamatsu City, Shizuoka, Japan
Tel 053-543-4543
Website https://www.hpharma.jp/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services